Barinthus Biotherapeutics plc’s immunotherapeutic against persistent, high-risk human papillomavirus (HPV) infections, VTP-200, was generally well-tolerated in a phase Ib/II study, but did not demonstrate significant signs of efficacy, pooled top-line data show.

Corner Therapeutics Inc. raised $54 million in a series A financing to create vaccines to protect against cancer and infectious diseases by helping the immune system engineer T cells. The company’s core interest is in advancements in immunotherapy through direct manipulation of T cells, which are the “keys to the kingdom for any cancer therapy,” Nick Seaver, Corner’s chief business officer, told BioWorld.

Cross talk between macrophages and tumor cells could modulate cachexia in pancreatic cancer patients. A group of scientists from the University of Oklahoma has discovered a new pathway that promoted muscle wasting after the recruitment of this immune cell in the tumor microenvironment, activating cachexia-inducing factors. Macrophage depletion and the inhibition of this signaling could be developed as a therapeutic target for this condition.

AR-V7 is the most clinically relevant androgen receptor (AR) splice variant associated with endocrine resistance and poor prognosis in patients with prostate cancer.

Researchers from Zhuhai Grit Biotechnology Co. Ltd. recently presented preclinical characterization of a new genetically modified tumor-infiltrating lymphocyte (TIL) product, GT-216, being developed for the treatment of solid tumors.

Using its artificial intelligence/machine learning platform, Aurigen, Auron Therapeutics Inc. has identified histone acetyltransferase KAT2A/B as a driver of tumor cell plasticity and designed new small-molecule degraders of KAT2A/B.